Since IVDs (in vitro diagnostics) have been regarded as a new trend in the diagnostic industry, IVD reagents have been widely used in the diagnosis of diseases, for monitoring drug therapies, and for determining prognosis. Currently, Creative Biolabs offers the best guarantee in the industry of IVD antibody development and has successfully launched a series of CDC25B phosphatase-specific antibody development services for our worldwide clients.
CDC25B phosphatase also known as M-phase inducer phosphatase 2, is an enzyme belonging to the CDC25 family of phosphatases. CDC25B phosphatase plays an essential role in cell cycle progression and is especially required for entry into mitosis. It activates the cyclin-dependent kinase (CDK) CDC2 by removing two phosphate groups. CDC25B phosphatase shuttles between the cytoplasm and the nucleus depending on the nuclear localization and nuclear export signals. It is unclear in the M and G1 phases of the cell cycle and transfers to the cytoplasm during S and G2. CDC25B phosphatase is supposed to be a mitotic regulator that may function as a ‘starter phosphatase’ to initiate the positive feedback loop at the entry into M phase. CDC25B is reported to have oncogenic properties, although its role in tumor formation has not been determined.
Colorectal cancer (CRC) is one of the most common malignancies around the world. The prognosis of patients with this disease remains the same during the past decades. The treatment for CRC is mainly based on surgical removal of the tumor, and approximately 50% of the patients die from this malignancy. Therefore, it is significant to identify a new biological marker which is different from the conventional clinicopathological factors to help select appropriate therapeutic methods. Dysregulation of cell cycle progression is one certain alteration in malignancies and CDC25B, which is involved in the cell cycle process, has been regarded to be potential oncogenes. By investigating the expression of CDC25B using immunohistochemistry in primary human colorectal cancer, as well as analyzing the correlation between prognosis and the level of CDC25B protein, studies have shown that CDC25B is a novel, independent, and promising prognostic marker for CRC.
Fig.1 Immunostaining with antihuman CDC25B antibody in normal colonic mucosa (A) and colorectal carcinoma tissues (B and C). (Takemasa, I., 2000)
Since CDC25B phosphatase is a novel prognostic marker in patients with colorectal cancer, Creative Biolabs is now glad to provide IVD antibody development services for CDC25B phosphatase. As a world-leading company in the field of antibody development, Creative Biolabs has vast experience with different formats of antibodies, including recombinant antibodies, bispecific antibodies, single domain antibodies, etc. We can offer the most comprehensive IVD antibody development services targeting various markers of CRC, including CDC25B phosphatase.
If you are interested in our services, please contact us to get more information.
Reference
For Research Use Only.
